A banner year for immunotherapy and targeted therapy

A banner year for immunotherapy and targeted therapyA banner year for immunotherapy and targeted therapy, Published online: 11 December 2018; doi:10.1038/s41571-018-0138-4In 2018, advances in the treatment of non-small-cell lung cancer (NSCLC) have been observed both in trials of immunotherapies and targeted agents, leading to dramatically improved options for patients with metastatic and stage III NSCLC.

https://www.nature.com/articles/s41571-018-0138-4

Source: Nature Clinical Practice Oncology - December 11, 2018 Category: Cancer & Oncology Authors: Jennifer W. Carlisle Suresh S. Ramalingam Source Type: research

More News: Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer